Bernstein Rates Natera (NTRA) buy, $310 Price Target
Bernstein reaffirms its buy rating on Natera, Inc. with a price target of $310, reflecting confidence in the company's future growth, a 16.09% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Bernstein rated Natera, Inc. ($NTRA) "buy" with a $310 price target on June 26, 2026.
Since the rating, $NTRA is up 8.4% after 1 week, down 1.5% after 1 month and up 50.2% to date (from the $261.91 close on Jun 26, 2026).
NTRA
Natera, Inc.
Key Points
- Bernstein reiterated its buy rating on Natera, Inc. with a price target of $310 on June 26, 2026.
- Bernstein's $310 price target implies 16.09% upside from Natera, Inc.'s ($NTRA) current $267.05 share price.
- Natera's stock is currently trading at $267.05, down from a 52-week high of $373.07, indicating potential for recovery.
- The consensus among analysts is strong, with a mean target price of $348.02 based on 23 opinions.
Get $NTRA trade alerts by text
We text you when insiders, Congress or big funds trade $NTRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
Bernstein Affirms Positive Outlook on Natera
On June 26, 2026, Bernstein reiterated its buy rating on Natera, Inc. (NTRA) with a price target of $310. The stock is currently trading at $267.05 on the NasdaqGS. This update reflects Bernstein's confidence in the company's growth potential and aligns with Natera's operations in the healthcare diagnostics sector.
Bernstein vs. the S&P 500
Hypothetical returns from Bernstein's disclosed trades, not real profit or advice. How we model this.
Analysts Set New Price Targets
Bernstein's reaffirmation comes as part of a broader positive sentiment among analysts. Recently, JP Morgan maintained an Overweight rating on Natera with a higher price target of $460 on October 14, 2026. Morgan Stanley also kept its Overweight rating, raising its target to $435 on October 13, 2026. Other firms, including TD Cowen and Barclays, have maintained similar bullish stances, with price targets ranging from $460 to $480. This consensus indicates that analysts expect the stock to perform well in the near future.
Stock Performance and Market Position
Natera's shares have seen fluctuations, trading well below their 200-day moving average of $306.30. The stock has a 52-week range from $157.43 to $373.07, suggesting a significant decline from its recent highs. This context makes Bernstein's price target of $310 appear optimistic yet achievable, especially as the company continues to innovate in the diagnostics space.
$NTRA price target
Natera, Inc. daily closes and this analyst's $310 target. Not advice.
Insider Buying and Selling at Natera, Inc.
On the same day as the Bernstein announcement, several insiders at Natera made notable purchases. Rowan Chapman bought 1,674 shares, while Lynch Thomas Jr. acquired 1,905 shares. Roelof Botha, Eric Rubin, and Roy Baynes also added to their stakes, purchasing 1,691, 75, and 1,646 shares, respectively. These transactions could signal confidence in the company’s future performance.
What Natera, Inc. Does
Natera, Inc. focuses on developing and commercializing molecular testing services. Its offerings include various cancer tests and genetic screenings. The company serves a wide range of clients, including laboratories and healthcare providers, which positions it well for future growth.
What’s Next for Natera
Looking ahead, investors should monitor Natera's upcoming earnings report scheduled for November 5, 2026. As a reminder, Bernstein's ratings and targets reflect past holdings and may not represent current positions. The recent analyst ratings and insider transactions suggest that confidence remains high in Natera's potential recovery and growth in the diagnostics sector.
Related Filing Alerts
Source: Bernstein's rating change on $NTRA (Jun 26, 2026). Written by software, not financial advice. How we make alerts